? Lynparza, the first PARP inhibitor from AstraZeneca $AZN to win US approval in 2014, has secured its third EU approval. The drug won the EMA nod for use patients with germline BRCA1/2-mutations and who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, partner?Merck $MRK said on Wednesday.
? A new protein degradation biotech has raised a $16 million launch round from a pair of Chinese venture groups. San Diego-based